ICA 3001
Alternative Names: ICA-3001Latest Information Update: 31 Oct 2024
At a glance
- Originator iCamuno Biotherapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Oct 2024 Preclinical trials in Cancer in China (Parenteral) (iCamuno Biotherapeutics pipeline, October 2024)